LONDON, August 17, 2016 /PRNewswire/ --

Clinical Chemistry, Immunochemistry, Haematology, Microbiology, Genetic Testing, Point of Care Diagnostics, Blood Glucose Testing, Infectious Diseases Testing, Rapid Cardiac Market Testing, Cholesterol Testing, Pregnancy Testing 

The In Vitro Diagnostics World Market 2016-2026: Clinical Chemistry, Immunochemistry, Haematology, Microbiology, Genetic Testing, Point of Care Diagnostics, Blood Glucose Testing, Infectious Diseases Testing, Rapid Cardiac Market Testing, Cholesterol Testing, Pregnancy Testing report assesses the global market for IVDs. The market is first split and forecasted by submarket.

Six main submarkets are covered, these are the:
• Point-of-care diagnostics (PoC)
• Clinical chemistry
• Immunochemistry
• Haematology
• Microbiology
• Genetic testing

The leading submarket in the IVD industry at present and throughout the next decade will be point-of-care diagnostics. This submarket is further subdivided into more specific tests. Blood glucose testing accounted for over half of the revenue PoC testing made in 2015 due to the rise in prevalence of diabetes.

What are the prospects in the leading regions and countries?
In our study you will find individual revenue forecasts to 2026 for the leading regional and national markets:
• US
• Japan
• Germany
• France
• UK

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

• Spain
• Italy
• China
• India
• Brazil
• Russia
• Rest of the World

The US, Japan and China were the 1st 2nd and 3rd leading national markets in 2015 and each will retain its place over the next 10 years. India will be the fastest growing national market from 2015-2026 with China close behind.

Our new report discusses issues and events affecting the IVD market. You will find discussions, including qualitative analyses on:
• The global IVD market
• The IVD market divided by submarket including; point-of-care, clinical chemistry, haematology, immunochemistry, microbiology and genetic testing
• The challenges facing the market, such as the US excise tax on medical devices
• The latest merger & acquisition activity amongst industry leaders
• 11 different national markets including the 'EU5' and 'BRIC' nations

Visiongain predicts that the demand for IVDs will increase in line with the rise in both incidence and prevalence of chronic and infectious diseases. Health professionals will recognise that if these diseases can be diagnosed at the earliest stage possible, then damage to the individual can be minimised in addition to a reduction of later costs to healthcare systems. IVDs will be able to stem the economic and clinical costs of chronic and infectious disease.

The drive to provide patients with diagnostic testing options that are more accurate, easy-to-use and convenient will sustain growth in the IVD market during the forecast period of this report.

Our 166 page report provides 38 tables and 72 figures covering 6 different IVD submarkets. 11 individual national markets are covered in addition to coverage of the leading companies in the industry. Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, a primary interview, industry trends, opportunities, and revenue predictions. The increasing prevalence of both chronic and infectious diseases will ensure that there is a great demand for use and innovation of IVDs over the next decade and beyond.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request a report overview of this report please emails Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1711/In-Vitro-Diagnostics-World-Market-2016-2026

Companies and Organisations Mentioned 

   
    3M
    Abbott Laboratories
    AbbVie
    Adaltis
    AdnaGen AG
    Affymetrix
    Agendia
    Agilent
    Akonni Biosystems
    Alere
    Amgen
    Arkay
    AssuraGen
    Astute Medical
    Atlas Genetics
    Bayer
    Beckman Coulter
    Binding Site
    Biohit HealthCare
    bioMérieux
    Bio-Rad
    BioSystems
    Bristol Myers-Squibb
    CardioGenics
    Celerus Diagnostics
    Center for Devices and Radiological Health (CDRH) [part of US FDA]
    Cepheid
    Claros Diagnostics
    Cognex
    Compendia Bioscience
    Corgenix
    Crescendo Bioscience
    Dako
    Danaher
    Daxor Corporation
    Devicor Medical Products
    DiaGenic
    DiaSorin
    Diaxonhit
    Diazyme Laboratories
    European Commission (EC)
    European Diagnostic Manufacturers Association (EDMA)
    European Medicines Agency (EMA)
    Expression Diagnostics
    Foundation for Innovative and New Diagnostics (FIND)
    Fujirebio Diagnostics Inc.
    Gene Chip Research Centre, Tianjin, China
    Genentech
    GenMark Diagnostics
    Genomic Health
    Gen-Probe
    Gifu University
    Glycominds
    Hai Kang Life Corporation
    Haplogen Genomics GmbH
    HemoCue
    Hoffman-La Roche
    Hologic
    Human Genetics Commission
    Immucell
    Immucor
    Innogenetics
    Innova Biotechnology Co.
    Instrumentation Laboratory
    Ipsogen
    Janssen Biotech
    Janssen Pharmaceuticals
    Japanese Ministry of Health and Welfare
    Johnson & Johnson
    Kreatech Diagnostics
    Lab-21
    LabIndia
    Launch Diagnostics
    Leica Microsystems
    Life Technologies
    LifeScan
    Luminex
    Med BioGene
    Melanoma Diagnostics
    Meridian Bioscience
    Milagen
    Mindray
    Miraca Life Sciences
    Myriad Genetics
    Nanosphere
    National Institute of Clinical Excellence (UK NICE)
    Novartis
    Onconome
    Orion Genomics
    Ortho Clinical Diagnostics
    PathWorks Diagnostics
    PerkinElmer
    Pharmaceutical and Medical Devices Agency, Japan (PMDA)
    Phillips
    Polymedco
    Qiagen
    Quest Diagnostics
    Radiometer Medical
    Randox Laboratories
    Response Biomedical
    Roche
    Rules-Based Medicine
    Saladax Biomedical
    Sanofi
    SDIX
    Sekisui Diagnostics
    Sera Prognostics
    SeraCare Life Sciences
    Siemens
    Span Diagnostics
    St Jude Medical
    Stago
    STARLIMS Technologies
    SterilMed
    Suzhou Ribo Life Sciences
    Synthes
    Sysmex
    Target Discovery
    Targeted Diagnostics & Therapeutics
    Tethys Bioscience
    The Carlyle Group
    Tocagen
    Tosoh Bioscience
    Transasia Bio Medicals
    Trinity Biotech
    United Nations (UN)
    UroSens
    US Food and Drug Administration (FDA)
    VentriPoint
    Verax Biomedical
    Vermillion
    ViiV Healthcare
    World Health Organization (WHO)

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

SOURCE Visiongain Ltd